Last edition
News about "Trastuzumab"
Roche Canada Completes pCPA Negotiations for Perjeta in Early HER2-Positive Breast Cancer
Roche Canada has completed pCPA negotiations for Perjeta in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive early-stage breast cancer, bringing the treatment closer to potential public reimbursement across Canada.
Trastuzumab | 20/08/2026 | By News Bureau
Anbenitamab Set to Lead as First Bispecific mAb in China's HER2+ Gastric Cancer Market: GlobalData
China’s NMPA has accepted Alphamab Oncology’s NDA for KN026 (Anbenitamab), which could become the first bispecific mAb for HER2-positive gastric and GEJ cancer, according to GlobalData.
Trastuzumab | 25/09/2025 | By Dineshwori | 400
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy